Moreover, the use of synthetic lethality extends to exploring combinations such as WEE1 G2 checkpoint kinase (Wee1) and checkpoint kinase 1 (CHK1) inhibitors in neuroendocrine prostate cancer (NEPC), with preclinical mouse models showing effective tumor growth inhibition. Here, CHEK1 is linked to neoplasm.